PHATHOM PHARMACEUTICALS, INC. Operating Cash Flow
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Operating Cash Flow of -$17.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.93M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$15.65M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.00M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$14.12M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$166.78M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$266.77M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$137.58M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$146.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$17.58M 10-Q · filed 2026-07-30 | -$22.58M derived: sum of 3 quarters · filed 2026-07-30 | -$36.69M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | -$15.65M 10-Q · filed 2026-04-30 | -$20.65M derived: sum of 2 quarters · filed 2026-04-30 | -$34.76M derived: sum of 3 quarters · filed 2026-04-30 | -$97.49M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$19.12M derived: sum of 2 quarters · filed 2026-02-26 | -$81.84M derived: sum of 3 quarters · filed 2026-07-30 | -$166.78M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$14.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$76.84M derived: sum of 2 quarters · filed 2026-07-30 | -$161.77M 10-Q · filed 2025-10-30 | -$225.23M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$62.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$147.66M 10-Q · filed 2026-07-30 | -$211.12M derived: sum of 3 quarters · filed 2026-07-30 | -$274.69M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$84.93M 10-Q · filed 2026-04-30 | -$148.39M derived: sum of 2 quarters · filed 2026-04-30 | -$211.96M derived: sum of 3 quarters · filed 2026-04-30 | -$282.68M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | -$63.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$127.03M derived: sum of 2 quarters · filed 2026-02-26 | -$197.75M derived: sum of 3 quarters · filed 2026-02-26 | -$266.77M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$63.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$134.29M derived: sum of 2 quarters · filed 2025-10-30 | -$203.31M 10-Q · filed 2025-10-30 | -$247.11M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | -$70.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$139.74M 10-Q · filed 2025-08-07 | -$183.54M derived: sum of 3 quarters · filed 2025-08-07 | -$215.45M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$69.02M 10-Q · filed 2025-05-01 | -$112.82M derived: sum of 2 quarters · filed 2025-05-01 | -$144.73M derived: sum of 3 quarters · filed 2025-05-01 | -$166.93M derived: sum of 4 quarters · filed 2025-05-01 | ||||
| 2023-12-31 | -$43.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$75.71M derived: sum of 2 quarters · filed 2025-03-06 | -$97.91M derived: sum of 3 quarters · filed 2025-03-06 | -$137.58M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$31.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$54.11M derived: sum of 2 quarters · filed 2024-11-07 | -$93.78M 10-Q · filed 2024-11-07 | -$134.82M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$22.20M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | -$61.87M 10-Q · filed 2024-08-08 | -$102.91M derived: sum of 3 quarters · filed 2024-08-08 | -$137.93M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$39.67M 10-Q/A · filed 2024-06-14 | -$80.71M derived: sum of 2 quarters · filed 2024-06-14 | -$115.73M derived: sum of 3 quarters · filed 2024-06-14 | -$141.44M derived: sum of 4 quarters · filed 2024-06-14 | ||||
| 2022-12-31 | -$41.04M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | -$76.06M derived: sum of 2 quarters · filed 2024-06-14 | -$101.77M derived: sum of 3 quarters · filed 2024-06-14 | -$146.53M 10-K/A · filed 2024-06-14 | ||||
| 2022-09-30 | -$35.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$60.73M derived: sum of 2 quarters · filed 2023-11-09 | -$105.49M 10-Q · filed 2023-11-09 | -$105.83M 10-Q · filed 2022-11-08 | -$146.75M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$25.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$70.47M 10-Q · filed 2023-08-10 | -$70.82M 10-Q · filed 2022-08-02 | -$111.73M derived: sum of 3 quarters · filed 2023-08-10 | -$140.80M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$44.76M 10-Q · filed 2023-05-10 | -$45.10M 10-Q · filed 2022-05-10 | -$86.02M derived: sum of 2 quarters · filed 2023-05-10 | -$115.08M derived: sum of 3 quarters · filed 2023-05-10 | -$143.45M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | -$41.26M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | -$70.33M derived: sum of 2 quarters · filed 2023-02-28 | -$98.69M derived: sum of 3 quarters · filed 2023-02-28 | -$148.46M 10-K · filed 2023-02-28 | -$148.62M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | -$29.07M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | -$57.43M derived: sum of 2 quarters · filed 2022-11-09 | -$107.19M 10-Q/A · filed 2022-11-09 | -$135.40M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$28.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$78.13M 10-Q · filed 2022-08-02 | -$106.33M derived: sum of 3 quarters · filed 2022-08-02 | -$127.06M derived: sum of 4 quarters · filed 2022-08-02 | ||||
| 2021-03-31 | -$49.77M 10-Q · filed 2022-05-10 | -$77.97M derived: sum of 2 quarters · filed 2022-05-10 | -$98.69M derived: sum of 3 quarters · filed 2022-05-10 | -$108.04M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$28.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$48.93M derived: sum of 2 quarters · filed 2022-03-01 | -$58.27M derived: sum of 3 quarters · filed 2022-03-01 | -$69.69M 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | -$20.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$30.07M derived: sum of 2 quarters · filed 2021-11-08 | -$41.49M 10-Q · filed 2021-11-08 | -$64.87M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | -$9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$20.76M 10-Q · filed 2021-08-10 | -$44.15M derived: sum of 3 quarters · filed 2021-08-10 | -$51.25M derived: sum of 4 quarters · filed 2021-08-10 | ||||
| 2020-03-31 | -$11.42M 10-Q · filed 2021-05-11 | -$34.80M derived: sum of 2 quarters · filed 2021-05-11 | -$41.91M derived: sum of 3 quarters · filed 2021-05-11 | -$47.12M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$23.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$30.49M derived: sum of 2 quarters · filed 2021-03-30 | -$35.70M derived: sum of 3 quarters · filed 2021-03-30 | -$36.51M 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | -$7.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$12.32M derived: sum of 2 quarters · filed 2020-11-10 | -$13.13M 10-Q · filed 2020-11-10 | -$13.43M derived: sum of 4 quarters · filed 2020-11-10 | ||||
| 2019-06-30 | -$5.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$6.02M 10-Q · filed 2020-08-06 | -$6.32M derived: sum of 3 quarters · filed 2020-08-06 | |||||
| 2019-03-31 | -$807.00K 10-Q · filed 2020-05-12 | -$1.11M derived: sum of 2 quarters · filed 2020-05-12 | ||||||
| 2018-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | -$1.02M 10-K · filed 2020-03-19 | ||||||
| 2018-09-30 | -$721.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |